Hematology/Oncology
RSSArticles
-
Pharmacology Watch: Is Naproxen the Safest NSAID for the Heart?
NSAIDs and cardiovascular risk; new antithrombotic guidelines; warfarin during surgery; Pfizer selling Viagra online; azithromycin and cardiovascular risk; and FDA actions. -
Phase 2 Study of Erlotinib Combined with Adjuvant Chemoradiation and Chemotherapy in Patients with Resectable Pancreatic Cancer
In a prospective Phase 2 study, 48 patients with resected pancreatic ductal adenocarcinoma were treated with erlotinib (100 mg daily) and capecitabine (800 mg/m2 twice daily Monday-Friday) concurrently with intensity-modulated radiation therapy followed by four cycles of adjuvant gemcitabine (1000 mg/m2 on days 1, 8, and 15 every 28 days) and erlotinib (100 mg daily). -
Clinical Briefs in Primary Care Supplement
-
The first ‘antibiotic steward’ warned this day would come
-
Vegas ex-doc gets life for HCV outbreak
-
Weight Gain with Contraception
The authors performed a two-part analysis of the contraceptive choice Project, a prospective cohort study in which women in the St. Louis, Missouri, region received a reversible contraceptive method of their choice for up to 3 years at no cost. -
"Off-target"; Effects? The Role of Statins in Cancer Biology
Cholesterol-reducing statin agents have been associated preclinically with cancer cell growth inhibition and metastases prevention. -
Risk of Uterine Rupture or Placenta Previa after Previous Myomectomy or Classical Cesarean
Conventional wisdom in obstetrics implies that woen with previous uterine surgery outside the lower uterine segment — whether myomectomy or classical cesarean section — incrue an unacceptable risk for uterine rupture during pregnancy. -
Clinical Briefs in Primary Care supplement
-
Testosterone — It’s Not the Magic Bullet
1998 was a landmark year for men’s sexuality. the FDA approved sildenafil (Viagra®), a medication that now has household name familiarity.